Supernus Pharmaceuticals ... (SUPN)
NASDAQ: SUPN
· Real-Time Price · USD
42.69
0.69 (1.64%)
At close: Aug 20, 2025, 10:01 AM
1.64% (1D)
| Bid | 42.58 |
| Market Cap | 2.39B |
| Revenue (ttm) | 665.13M |
| Net Income (ttm) | 64.5M |
| EPS (ttm) | 1.15 |
| PE Ratio (ttm) | 37.12 |
| Forward PE | 17.12 |
| Analyst | Hold |
| Ask | 42.79 |
| Volume | 56,179 |
| Avg. Volume (20D) | 781,245 |
| Open | 42.15 |
| Previous Close | 42.00 |
| Day's Range | 41.78 - 42.96 |
| 52-Week Range | 29.16 - 43.73 |
| Beta | 0.74 |
About SUPN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SUPN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Supernus Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+13.08%
Supernus Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
6 months ago
-15.67%
Supernus Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from Overweight to Neutral and cut its price target from $57 to $36.
2 weeks ago · seekingalpha.com
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call TranscriptSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.
